Contrasting impacts of immunosuppressive agents (rapamycin, FK506, cyclosporin A, and dexamethasone) on bidirectional dendritic cell-T cell interaction during antigen presentation

Journal of Immunology

Volumn 169, Issue 7, 2002, Pages 3555-3564

  Matsue, Hiroyuki ^a   Yang, Chendong ^a   Matsue, Keiko ^a   Edelbaum, Dale ^a   Mummert, Mark ^a   Takashima, Akira ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD40 ANTIGEN; CD69 ANTIGEN; CHEMOKINE RECEPTOR CCR7; CYCLOSPORIN A; CYTOKINE; DEXAMETHASONE; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 12; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; MESSENGER RNA; OVALBUMIN; RAPAMYCIN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 12; RECOMBINANT INTERLEUKIN 4; TACROLIMUS;

ANIMAL CELL; ANIMAL MODEL; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; APOPTOSIS; ARTICLE; BONE MARROW CELL; CELL INTERACTION; CELL VIABILITY; CONTROLLED STUDY; DENDRITIC CELL; IMMUNOSUPPRESSIVE TREATMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TRANSGENIC MOUSE;

EID: 0036784638     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.169.7.3555     Document Type: Article

References (56)

1. Kiani, A., A. Rao, and J. Aramburu. 2000. Manipulating immune responses with immunosuppressive agents that target NFAT. Immunity 12:359.
2. 2+, calcineurin, and NF-AT. Cell 96:611.
3. Brazelton, T. R., and R. E. Morris. 1996. Molecular mechanisms of action of new xenobiotic immunosuppressive drugs: tacrolimus (FK506), sirolimus (rapamycin), mycophenolate mofetil and leflunomide. Curr. Opin. Immunol. 8:710.
4. Sehgal, S. N. 1998. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin. Biochem. 31:335.
5. Abraham, R. T., and G. J. Wiederrecht. 1996. Immunopharmacology of rapamycin. Annu. Rev. Immunol. 14:483.
6. Abraham, R. T. 1998. Mammalian target of rapamycin: immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling. Curr. Opin. Immunol. 10:330.
7. Akerblom, I. E., E. P. Slater, M. Beato, J. D. Baxter, and P. L. Mellon. 1988. Negative regulation by glucocorticoids through interference with a cAMP responsive enhancer. Science 241:350.
8. Auphan, N., J. A. DiDonato, C. Rosette, A. Helmberg, and M. Karin. 1995. Immunosuppression by glucocorticoids: inhibition of NF-κB activity through induction of IκB synthesis. Science 270:286.
9. Scheinman, R. I., A. Gualberto, C. M. Jewell, J. A. Cidlowski, and A. S. Baldwin, Jr. 1995. Characterization of mechanisms involved in transrepression of NF-κB by activated glucocorticoid receptors. Mol. Cell Biol. 15:943.
10. Van Laethem, F., E. Baus, L. A. Smyth, F. Andris, F. Bex, J. Urbain, D. Kioussis, and O. Leo. 2001. Glucocorticoids attenuate T cell receptor signaling. J. Exp. Med. 193:803.
11. Dumont. F. J., M. J. Staruch, P. Fischer, C. DaSilva, and R. Camacho. 1998. Inhibition of T cell activation by pharmacologic disruption of the MEK1/ERK MAP kinase or calcineurin signaling pathways results in differential modulation of cytokine production. J. Immunol. 160:2579.
12. Metcalfe, S. M., and F. M. Richards. 1990. Cyclosporine, FK506, and rapamycin: some effects on early activation events in serum-free, mitogen-stimulated mouse spleen cells. Transplantation 49:798.
13. Dumont, F. J., M. J. Staruch, S. L. Koprak. M. R. Melino, and N. H. Sigal. 1990. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. J. Immunol. 144:251.
14. Dumont, F. J., M. R. Melino, M. J. Staruch, S. L. Koprak, P. A. Fischer, and N. H. Sigal. 1990. The immunosuppressive macrolides FK-506 and rapamycin act as reciprocal antagonists in murine T cells. J. Immunol. 144:1418.
15. Arya, S. K., F. Wong-Staal, and R. C. Gallo. 1984. Dexamethasone-mediated inhibition of human T cell growth factor and γ-interferon messenger RNA. J. Immunol. 133:273.
16. Furue, M., and Y. Ishibashi. 1991. Differential regulation by dexamethasone and cyclosporine of human T cells activated by various stimuli. Transplantation 52: 522.
17. Kahan, B, D., and J. S. Camardo. 2001. Rapamycin: clinical results and future opportunities. Transplantation 72:1181.
18. Banchereau, J., and R. M. Steinman. 1998. Dendritic cells and the control of immunity. Nature 392:245.
19. Lee, J. I., R. W. Ganster, D. A. Geller, G. J. Burckart, A. W. Thomson, and L. Lu. 1999. Cyclosporine A inhibits the expression of costimulatory molecules on in vitro-generated dendritic cells: association with reduced nuclear translocation of nuclear factor κB. Transplantation 68:1255.
20. Woltman, A. M., J. W. de Fijter, S. W. Kamerling, L. C. Paul, M. R. Daha, and C. van Kooten. 2000. The effect of calcineurin inhibitors and corticosteroids on the differentiation of human dendritic cells. Eur. J. Immunol. 30:1807.
21. Piemonti, L., P. Monti, P. Allavena, M. Sironi, L. Soldini, B. E. Leone, C. Socci, and C. Di, V. 1999. Glucocorticoids affect human dendritic cell differentiation and maturation. J. Immunol. 162:6473.
22. Manome, H., S. Aiba, S. Singh, Y. Yoshino, and H. Tagami. 2000. Dexamethasone and cyclosporin A affect the maturation of monocyte-derived dendritic cells differently. Int. Arch. Allergy Immunol. 122:76.
23. Rea, D., C. van Kooten, K. E. van Meijgaarden, T. H. Ottenhoff, C. J. Melief, and R. Offringa. 2000. Glucocorticoids transform CD40-triggering of dendritic cells into an alternative activation pathway resulting in antigen-presenting cells that secrete IL-10. Blood 95:3162.
24. Woltman, A. M., J. W. de Fijter, S. W. Kamerling, S. W. van der Kooij, L. C. Paul, M. R. Daha, and C. van Kooten. 2001. Rapamycin induces apoptosis in monocyte- and CD34-derived dendritic cells but not in monocytes and macrophages. Blood 98:174.
25. Caux, C., C. Massacrier, B. Vanbervliet, B. Dubois, C. van Kooten, I. Durand, and J. Banchereau. 1994. Activation of human dendritic cells through CD40 cross-linking. J. Exp. Med. 180:1263.
26. Morelli, A. E., A. F. Zahorchak, A. T. Larregina, B. L. Colvin, A. J. Logar, T. Takayama, L. D. Falo, and A. W. Thomson. 2001. Cytokine production by mouse myeloid dendritic cells in relation to differentiation and terminal maturation induced by lipopolysaccharide or CD40 ligation. Blood 98:1512.
27. Cella. M., D. Scheidegger, K. Palmer-Lehmann, P. Lane, and G. Alber. 1996. Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J. Exp. Med. 184:747.
28. Koch, F., U. Stanzl, P. Jennewein, K. Janke, C. Heufler, E. Kämpgen, N. Romani, and G. Schuler. 1996. High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. J. Exp. Med. 184:741.
29. Kitajima, T., K. Ariizumi, M. Mohamadzadeh, D. Edelbaum, P. R. Bergstresser, and A. Takashima. 1995. T cell-dependent secretion of IL-1β by a dendritic cell line (XS52) derived from murine epidermis. J. Immunol. 155:3794.
30. Kitajima, T., K. Ariizumi, P. R. Bergstresser, and A. Takashima. 1995. T cell-dependent loss of proliferative responsiveness to colony-stimulating factor-1 by a murine epidermal-derived dendritic cell line, XS52. J. Immunol. 155:5190.
31. Kitajima, T., G. Caceres-Dittmar, F. J. Tapia, J. Jester, P. R. Bergstresser, and A. Takashima. 1996. T cell-mediated terminal maturation of dendritic cells: Loss of adhesive and phagocytotic capacities. J. Immunol. 157:2340.
32. lo thymocytes in vivo. Science 250: 1720.
33. Randolph, D. A., C. J. L. Carruthers, S. J. Szabo, K. M. Murphy, and D. D. Chaplin. 1999. Modulation of airway inflammation by passive transfer of allergen-specific Th1 and Th2 in a mouse model of asthma. J. Immunol. 162: 2375.
34. Matsue, H., K. Matsue, M. Walters, K. Okumura, H. Yagita, and A. Takashima. 1999. Induction of antigen-specific immunosuppression by CD95L cDNA-transfected "killer" dendritic cells. Nat. Med. 5:930.
35. Inaba, K., M. Inaba, N. Romani, H. Aya, M. Deguchi, S. Ikehara, S. Muramatsu, and R. M. Steinman. 1992. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J. Exp. Med. 176:1693.
36. Kumamoto, T., E. K. Huang, H. J. Paek, R. F. Valentini, and A. Takashima. 2002. Induction of tumor-specific protective immunity by in situ Langerhans cell vaccine. Nat. Biotechnol. 20:64.
37. Schmittgen, T. D., B. A. Zakrajsek, A. G. Mills, V. Gorn, M. J. Singer, and M. W. Reed. 2000. Quantitative reverse transcription-polymerase chain reaction to study mRNA decay: comparison of endpoint and real-time methods. Anal. Biochem. 285:194.
38. Yamaguchi, Y., H. Tsumura, M. Miwa, and K. Inaba. 1997. Contrasting effects of TGF-β1 and TNF-α on the development of dendritic cells from progenitors in mouse bone marrow. Stem Cells 15:144.
39. Yanagihara, S., E. Komura, J. Nagafune, H. Watari, and Y. Yamaguchi. 1998. EBI1/CCR7 is a new member of dendritic cell chemokine receptor that is up-regulated upon maturation. J. Immunol. 161:3096.
40. Sozzani, S., P. Allavena, G. D'Amico, W. Luini, G. Bianchi, M. Kataura, T. Imai, O. Yoshie, R. Bonecchi, and A. Mantovani. 1998. Differential regulation of chemokine receptors during dendritic cell maturation: a model for their trafficking properties. J. Immunol. 161:1083.
41. Sallusto, F., P. Schaerli, P. Loetscher, C. Schaniel, D. Lenig, C. R. Mackay, S. Qin, and A. Lanzavecchia. 1998. Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation. Eur. J. Immunol. 28:2760.
42. + T cells toward Th2 responses. J. Leukocyte Biol. 68:633.
43. Szabo, G., C. Gavala, and P. Mandrekar. 2001. Tacrolimus and cyclosporine A inhibit allostimulatory capacity and cytokine production of human myeloid dendritic cells. J. Invest. Med. 49:442.
44. + T-cell phenotype development. Proc. Natl. Acad. Sci. USA 92:7565.
45. Vanasek. T. L., A. Khoruts, T. Zell, and D. L. Mueller. 2001. Antagonistic roles for CTLA-4 and the mammalian target of rapamycin in the regulation of clonal anergy: enhanced cell cycle progression promotes recall antigen responsiveness. J. Immunol. 167:5636.
46. Oellerich, M., V. W. Armstrong, E. Schutz, and L. M. Shaw. 1998. Therapeutic drug monitoring of cyclosporine and tacrolimus: update on Lake Louise Consensus Conference on cyclosporin and tacrolimus. Clin. Biochem. 31:309.
47. Saunders, R. N., M. S. Metcalfe, and M. L. Nicholson. 2001. Rapamycin in transplantation: a review of the evidence. Kidney Int. 59:3.
48. Bundick, R. V., R. I. Craggs, and E. Holness. 1995. The effect of cyclosporin A, FK506, and rapamycin on the murine chronic graft-versus-host response: an in vivo model of Th2-like activity. Clin. Exp. Immunol. 99:467.
49. Warner, L. M., L. M. Adams, and S. N. Sehgal. 1994. Rapamycin prolongs survival and arrests pathophysiologic changes in murine systemic lupus erythematosus. Arthritis Rheum. 37:289.
50. Carlson, R. P., W. L. Baeder, R. G. Caccese, L. M. Warner, and S. N. Sehgal. 1993. Effects of orally administered rapamycin in animal models of arthritis and other autoimmune diseases, Ann. NY Acad. Sci. 685:86.
51. Vogelsang, G. B., and A. D. Hess. 1993. Rapamycin effects on immunologic reconstitution. Transplant. Proc. 25:727.
52. Luo. H., W. Duguid, H. Chen, M. Maheu, and J. Wu. 1994. The effect of rapamycin on T cell development in mice. Eur. J. Immunol. 24:692.
53. Hess, A. D., and C. J. Thoburn. 1997. Immunobiology and immunotherapeutic implications of syngeneic/autologous graft-versus-host disease. Immunol. Rev. 157:111.
54. Wang, M. E., S. M. Stepkowski, M. Ferraresso, and B. D. Kahan. 1992. Evidence that rapamycin rescue therapy delays rejection of major (MHC) plus minor (non-MHC) histoincompatible heart allografts in rats. Transplantation 54:704.
55. Carlson, R. P., D. A. Hartman, L. A. Tomchek, T. L. Walter, J. R. Lugay, W. Calhoun, S. N. Sehgal, and J. Y. Chang. 1993. Rapamycin, a potential disease-modifying antiarthritic drug. J. Pharmacol. Exp. Ther. 266:1125.
56. Li, Y., X. C. Li, X. X. Zheng, A. D. Wells, L. A. Turka, and T. B. Strom. 1999. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat. Med. 5:1298.